ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it has initiated a Phase 2 clinical ...

We recently published 10 Stocks Leaving Wall Street in the Dust; 4 Hit Fresh Records. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Tuesday. ImmunityBio extended its winning streak ...

ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...

ImmunityBio, Inc. (NASDAQ:IBRX) is among the 12 Best Performing Stocks in February. On March 4, 2026, Piper Sandler analyst Patrick Soon-Shiong increased ImmunityBio, Inc. (NASDAQ:IBRX)’s price ...

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its supplemental Biologics License ...

Shares of Culver City-based ImmunityBio Inc. surged yet again late last month to nearly a five-year high as its immunotherapy ...

We recently published 10 Big Names With Effortless Double-Digit Gains. ImmunityBio Inc. (NASDAQ:IBRX) was one of the best ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX) (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...

ImmunityBio's recently approved cancer drug has plenty of momentum. However, valuation concerns and clinical and regulatory ...

Q4 2025 Earnings Call March 3, 2026 4:30 PM ESTCompany ParticipantsPatrick Soon-Shiong - Founder, Executive Chairman and ...